Photo of Beverly Moy,  MD, MPH

Beverly Moy, MD, MPH

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-1074
Fax: (617) 724-1079


bmoy@partners.org

Beverly Moy, MD, MPH

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Clinical Director, Gillette Center for Women's Cancers - Center for Breast Cancer, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Beverly Moy, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and the Clinical Director of the Breast Oncology Program specializing in Medical Oncology at the Massachusetts General Hospital. She received her undergraduate education at the Johns Hopkins University and her medical degree at the Albert Einstein College of Medicine. She completed her internal medicine residency training at Brigham and Women’s Hospital and her hematology-oncology fellowship at Beth Israel Deaconess Medical Center. She received a Master's degree in Public Health at the Harvard School of Public Health. Her specific research interests include cancer disparities, ethics, and breast cancer clinical trials. She has served as Chair of the American Society of Clinical Oncology’s Ethics Committee and Disparities Committee. She is a columnist for ascoconnection.org and an editorial board member of HemOnc Today and the National Cancer Institute’s Adult Treatment Patient Data Query Editorial Board. She also serves as the Physician Leader of the MGH Avon Breast Care and Community Outreach Program and the MGH Lazarex Cancer Care Equity Program.

Publications

Powered by Harvard Catalyst
  • Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE, . Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer 2015; 51:685-96. PubMed
  • Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer 2015. PubMed
  • Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol 2015; 33:340-8. PubMed
  • Moy B, Specht MC, Lanuti M, Rafferty EA, Lerwill MF. Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy. N Engl J Med 2015; 372:162-70. PubMed
  • Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372:134-41. PubMed
  • Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 2014. PubMed
  • Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC. Geriatric Oncology for the 21st Century: A Call for Action. J Oncol Pract 2014. PubMed
  • Lennes IT, Bloom M, Bohlen N, Moy B. Massachusetts general hospital: improving patient access to the breast oncology clinic. J Natl Compr Canc Netw 2014; 12 Suppl 1:S25-7. PubMed
  • Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist 2014; 19:186-92. PubMed
  • Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I. Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. Oncologist 2014; 19:346-7. PubMed
  • Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I. Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. Oncologist 2014; 19:348-9. PubMed
  • Jagsi R, Sulmasy DP, Moy B. Value of cancer care: ethical considerations for the practicing oncologist. Am Soc Clin Oncol Educ Book 2014; 34:e146-9. PubMed
  • Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer 2014; 119:3943-51. PubMed
  • Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013; 142:405-14. PubMed
  • Moy B, Bradbury AR, Helft PR, Egleston BL, Sheikh-Salah M, Peppercorn J. Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol 2013; 31:2678-84. PubMed
  • Kumar P, Moy B. Cancer health disparities and the cost of cancer care: payment model issues. J Natl Compr Canc Netw 2013; 11:633-6. PubMed
  • Kumar P, Moy B. The Cost of Cancer Care--Balancing Our Duties to Patients Versus Society: Are They Mutually Exclusive? Oncologist 2013. PubMed
  • Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, . Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14:88-96. PubMed
  • Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ. Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. Biomed Opt Express 2014; 4:2911-24. PubMed
  • Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 2012; 14:R129. PubMed
  • Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers 2012. PubMed
  • Raj A, Ko N, Battaglia TA, Chabner BA, Moy B. Patient navigation for underserved patients diagnosed with breast cancer. Oncologist 2012; 17:1027-31. PubMed
  • Sepucha KR, Belkora JK, Chang Y, Cosenza C, Levin CA, Moy B, Partridge A, Lee CN. Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery. BMC Med Inform Decis Mak 2012; 12:51. PubMed
  • Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA. American society of clinical oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol 2011; 29:3816-24. PubMed
  • Morris PG, Chen C, Steingart RM, Fleisher M, Lin NU, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler MN, McArthur HL, Winer EP, Norton L, Hudis C, Dang CT. Troponin I and C-Reactive Protein are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. Clin Cancer Res 2011. PubMed
  • Lee CN, Belkora J, Chang Y, Moy B, Partridge A, Sepucha K. Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article]. Plast Reconstr Surg 2011; 127:18-26. PubMed
  • Moy B, Chabner BA. Patient navigator programs, cancer disparities, and the patient protection and affordable care act. Oncologist 2011; 16:926-9. PubMed
  • Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 2010; 28:2982-8. PubMed
  • Swan JS, Ying J, Stahl J, Kong CY, Moy B, Roy J, Halpern E. Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing. Qual Life Res 2010; 19:401-12. PubMed
  • Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 2009; 27:6117-23. PubMed
  • Ozanne EM, Partridge A, Moy B, Ellis KJ, Sepucha KR. Doctor-patient communication about advance directives in metastatic breast cancer. J Palliat Med 2009; 12:547-53. PubMed
  • Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S, Goold SD. Institutional academic industry relationships. JAMA 2007; 298:1779-86. PubMed
  • Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology 2007; 16:895-903. PubMed
  • Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12:756-65. PubMed
  • Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology 2007. PubMed
  • del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS. Mammographic breast density and race. AJR Am J Roentgenol 2007; 188:1147-50. PubMed
  • Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 2007; 7:489-92. PubMed
  • Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11:1047-57. PubMed
  • Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 2006; 17:1637-43. PubMed
  • Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 2006; 12:4790-3. PubMed
  • Moy B, Park ER, Feibelmann S, Chiang S, Weissman JS. Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women. Psychooncology 2006; 15:623-34. PubMed
  • Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005; 23:8340-7. PubMed
  • Blanchard K, Colbert JA, Puri D, Weissman J, Moy B, Kopans DB, Kaine EM, Moore RH, Halpern EF, Hughes KS, Tanabe KK, Smith BL, Michaelson JS. Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer 2004; 101:495-507. PubMed
  • Campbell EG, Moy B, Feibelmann S, Weissman JS, Blumenthal D. Institutional academic industry relationship: results of interviews with university leaders. Account Res 2005; 11:103-18. PubMed
  • Moy B, Wang JC, Raffel GD, Marcoux JP. Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med 2000; 160:1370-2. PubMed
  • Sepucha KR,Ozanne EM,Partridge AH,Moy B. Is There a Role for Decision Aids in Advanced Breast Cancer? Med Decis Making 2009; 29:475-82. PubMed
Hide